SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-23-165267
Filing Date
2023-06-12
Accepted
2023-06-12 16:01:54
Documents
12
Period of Report
2023-06-12
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers

Document Format Files

Seq Description Document Type Size
1 8-K d513663d8k.htm   iXBRL 8-K 28279
  Complete submission text file 0001193125-23-165267.txt   151084

Data Files

Seq Description Document Type Size
2 XBRL TAXONOMY EXTENSION SCHEMA rgls-20230612.xsd EX-101.SCH 2857
3 XBRL TAXONOMY EXTENSION LABEL LINKBASE rgls-20230612_lab.xml EX-101.LAB 17995
4 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE rgls-20230612_pre.xml EX-101.PRE 11266
6 EXTRACTED XBRL INSTANCE DOCUMENT d513663d8k_htm.xml XML 3359
Mailing Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121
Business Address 4224 CAMPUS POINT COURT SUITE 210 SAN DIEGO CA 92121 858-202-6300
Regulus Therapeutics Inc. (Filer) CIK: 0001505512 (see all company filings)

IRS No.: 264738379 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-35670 | Film No.: 231007987
SIC: 2834 Pharmaceutical Preparations